Loading
A phase 3 trial of Pertuzumab in advanced solid tumours, run by BioRay Pharmaceutical Co., Ltd., active and no longer recruiting.
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel is a phase 3 interventional study registered as NCT04514419 by BioRay Pharmaceutical Co., Ltd., with 408 participants enrolled, started 2020-06-28 and due to reach its primary completion in 2024-09-11. Interventions recorded: HS627 and Pertuzumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pertuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/